Bausch Health Companies (BHC) vs SELLAS Life Sciences Group (SLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
SELLAS Life Sciences Group (SLS) has outperformed Bausch Health Companies (BHC) over the past year, gaining 495.3% versus a loss of 3.8%. Over five years, SLS leads with a +28.1% price change compared with -78.4% for BHC. SELLAS Life Sciences Group is the larger company by market cap ($2.27 billion vs $2.26 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHC | SLS |
|---|---|---|
| Share price | $6.04 | $11.26 |
| Market cap | $2.26B | $2.27B |
| 1-day change | -1.79% | -0.44% |
| YTD return | -11.51% | +200.00% |
| 1-year return | -3.76% | +495.26% |
| 5-year return | -78.41% | +28.09% |
| Forward P/E | 1.44 | — |
| EPS (TTM) | $-2.95 | $-0.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.00 | $15.88 |
| 52-week low | $4.33 | $1.39 |
| Distance from 52-week high | -24.50% | -29.09% |
| Analyst consensus | hold | none |
| Avg. price target upside | +24.17% | +188.63% |
| Average volume | 3.24M | 6.56M |
| Shares outstanding | 373.99M | 201.95M |
| Employees | 20,300 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLS has outperformed BHC by 499.0 percentage points over the past year.
About Bausch Health Companies
BHC stock →Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company.
Health Care · Biotechnology: Pharmaceutical Preparations · 20,300 employees
About SELLAS Life Sciences Group
SLS stock →SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
BHC vs SLS FAQ
Which is bigger, Bausch Health Companies or SELLAS Life Sciences Group?
SELLAS Life Sciences Group (SLS) is larger, with a market capitalization of $2.27B compared with $2.26B for Bausch Health Companies (BHC).
Which stock has performed better over the past year, BHC or SLS?
SLS returned +495.26% over the past 12 months, compared with -3.76% for BHC (price return, excluding dividends). Past performance does not predict future results.
Are Bausch Health Companies and SELLAS Life Sciences Group in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.